132 related articles for article (PubMed ID: 8095749)
1. Down-regulation of epidermal growth factor receptors by dithranol.
Kemény L; Michel G; Arenberger P; Ruzicka T
Acta Derm Venereol; 1993 Feb; 73(1):37-40. PubMed ID: 8095749
[TBL] [Abstract][Full Text] [Related]
2. Dithranol-induced down-regulation of 12(S)-hydroxyeicosatetraenoic acid [12(S)-HETE] receptors in a human epidermal cell line.
Kemény L; Gross E; Arenberger P; Ruzicka T
Arch Dermatol Res; 1991; 283(5):333-6. PubMed ID: 1656897
[TBL] [Abstract][Full Text] [Related]
3. Anthralin decreases keratinocyte TGF-alpha expression and EGF-receptor binding in vitro.
Gottlieb AB; Khandke L; Krane JF; Staiano-Coico L; Ashinoff R; Krueger JG
J Invest Dermatol; 1992 May; 98(5):680-5. PubMed ID: 1314863
[TBL] [Abstract][Full Text] [Related]
4. Topical application of dithranol on normal skin induces epidermal hyperproliferation and increased Ks8.12 binding.
de Zwart AJ; de Jong EM; van de Kerkhof PC
Skin Pharmacol; 1992; 5(1):34-40. PubMed ID: 1374264
[TBL] [Abstract][Full Text] [Related]
5. Anthralin (dithranol) in vitro inhibits human monocytes to secrete IL-6, IL-8 and TNF-alpha, but not IL-1.
Mrowietz U; Jessat H; Schwarz A; Schwarz T
Br J Dermatol; 1997 Apr; 136(4):542-7. PubMed ID: 9155955
[TBL] [Abstract][Full Text] [Related]
6. Dithranol upregulates IL-10 receptors on the cultured human keratinocyte cell line HaCaT.
Farkas A; Kemény L; Szöny BJ; Bata-Csörgö Z; Pivarcsi A; Kiss M; Széll M; Koreck A; Dobozy A
Inflamm Res; 2001 Jan; 50(1):44-9. PubMed ID: 11235021
[TBL] [Abstract][Full Text] [Related]
7. Dithranol: a review of the mechanism of action in the treatment of psoriasis vulgaris.
Kemény L; Ruzicka T; Braun-Falco O
Skin Pharmacol; 1990; 3(1):1-20. PubMed ID: 2202336
[TBL] [Abstract][Full Text] [Related]
8. An immunohistochemical assessment of the response of the psoriatic lesion to single and repeated applications of high-dose dithranol cream.
Swinkels OQ; Prins M; Gerritsen MJ; van Vlijmen-Willems IM; van der Valk PG; van de Kerkhof PC
Skin Pharmacol Appl Skin Physiol; 2002; 15(6):393-400. PubMed ID: 12476013
[TBL] [Abstract][Full Text] [Related]
9. Effects of anthralin and hypericin on growth factor signalling and cell proliferation in vitro.
Richter A; Davies DE
Biochem Pharmacol; 1995 Dec; 50(12):2039-45. PubMed ID: 8849331
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of epidermal growth factor binding to cultured mouse epidermal cells by tumor promoters.
Murray AW; Froscio M
Carcinogenesis; 1980 Aug; 1(8):681-4. PubMed ID: 11272121
[TBL] [Abstract][Full Text] [Related]
11. Oxidation of antipsoriatic 10-acyldithranol derivatives and dithranol to 1,8-dihydroxyanthraquinone.
Taskinen J; Haarala J; Wartiovaara E; Halmekoski J
Arch Pharm (Weinheim); 1988 Feb; 321(2):103-6. PubMed ID: 3369924
[No Abstract] [Full Text] [Related]
12. Epidermal differentiation characteristics of the psoriatic plaque during short contact treatment with dithranol cream.
van der Vleuten CJ; de Jong EM; van de Kerkhof PC
Clin Exp Dermatol; 1996 Nov; 21(6):409-14. PubMed ID: 9167334
[TBL] [Abstract][Full Text] [Related]
13. The effect on epidermal DNA synthesis of a combination of topical steroid with either dithranol or tar as used for psoriasis.
Clement M; Hehir M; Phillips H; du Vivier A
Br J Dermatol; 1983 Sep; 109(3):327-35. PubMed ID: 6615719
[TBL] [Abstract][Full Text] [Related]
14. Effects of the antipsoriatic drug dithranol on E2A and caspase-9 gene expression in vitro.
Ronpirin C; Tencomnao T
Genet Mol Res; 2012 Feb; 11(1):412-20. PubMed ID: 22370944
[TBL] [Abstract][Full Text] [Related]
15. An investigation of the ability of antipsoriatic drugs to inhibit calmodulin activity: a possible mode of action of dithranol (anthralin).
Tucker WF; MacNeil S; Dawson RA; Tomlinson S; Bleehen SS
J Invest Dermatol; 1986 Aug; 87(2):232-5. PubMed ID: 3016102
[TBL] [Abstract][Full Text] [Related]
16. Dithranol-mediated, dose-dependent priming and activation of luminol-enhanced chemiluminescence responses of human neutrophils in vitro.
Anderson R
Br J Dermatol; 1989 Jul; 121(1):1-9. PubMed ID: 2757949
[TBL] [Abstract][Full Text] [Related]
17. Electron microscopy of the effects of dithranol on healthy and on psoriatic skin.
Kanerva L
Am J Dermatopathol; 1990 Feb; 12(1):51-62. PubMed ID: 2316816
[TBL] [Abstract][Full Text] [Related]
18. The interleukin-8 receptor: a potential target for antipsoriatic therapy?
Kemény L; Kenderessy AS; Olasz E; Michel G; Ruzicka T; Farkas B; Dobozy A
Eur J Pharmacol; 1994 Jun; 258(3):269-72. PubMed ID: 8088360
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporin A, FK506 and dithranol after tyrosine-specific protein phosphorylation in HaCaT keratinocytes.
Ockenfels HM; Nussbaum G; Schultewolter T; Burger PM; Goos M
Arch Dermatol Res; 1995; 287(3-4):304-9. PubMed ID: 7541191
[TBL] [Abstract][Full Text] [Related]
20. Effects of treatment with dithranol, etretinate and a combination of dithranol and etretinate on epidermal metabolism and histology. Mouse tail assay.
Lubach D; Kietzmann M
Arzneimittelforschung; 1988 Aug; 38(8):1167-70. PubMed ID: 3196412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
